<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">IFN-α is a broad-spectrum antiviral drug, which could inhibit the synthesis of viral RNA and inhibit viral replication and spread. IFN-α, combined with ribavirin, which could reduce viral replication, moderated the host response and improved clinical outcome in MERS-CoV infected rhesus macaques [
 <xref ref-type="bibr" rid="CR2">2</xref>]. In China, IFN-α is available in injections, sprays, gels, etc. IFN-α nebulization or spray are commonly used in children for treating bronchiolitis [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR4">4</xref>], herpes angina [
 <xref ref-type="bibr" rid="CR5">5</xref>, 
 <xref ref-type="bibr" rid="CR6">6</xref>], hand-foot-mouth disease [
 <xref ref-type="bibr" rid="CR7">7</xref>, 
 <xref ref-type="bibr" rid="CR8">8</xref>], etc. In the experts' consensus statements, it could be also used for treatment of COVID-19 in children [
 <xref ref-type="bibr" rid="CR9">9</xref>], IFN-α is the only antiviral drug which is clearly recommended to be used in children with COVID-19.
</p>
